Gastric & Breast Cancer e-journal
DOI: 10.2122/gbc.2011.0149
NEWS & VIEWS
|
Breast cancer: New key phase 3 trials data on sentinel node, recurrence biopsy and bevacizumab
|
Eleftheria Ignatiadou, M.D. and Charalabos Batsis, M.D.
|
Affiliation: Dr. Eleftheria Ignatiadou, and Charalabos Batsis, Assistant Professor of Surgery, Department of Surgery, University Hospital of Ioannina, Ioannina, TK 45110, Greece.
E-mail: chbatsis@hotmail.com |
Since there is no abstract available we provide the first paragraph.
Data with major clinical utility for patients, physicians, medical and surgical oncologists were released at the ASCO 2010 meeting from large-scale phase 3 trials before the full publication. No prognostic significance had occult metastasis (micrometastasis) in sentinel node biopsy and no survival benefit was associated with bevacizumab treatment.
(Citation: Gastric & Breast Cancer
2011; 10(1): 43-46)
|
|
| You can have an online full-text access and a PDF of this article: |
- Either purchase this paper for €33 EUR. Please, click here
|
|
- Or through one year subscription PayPal
|
|
